
ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

Dr. Stella Lee explores the past, present and future implementation of guidelines into daily practice

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.